Clinical Research > Product Research

Product Research

The Pelargonium sidoides extract (EPs 7630) 1X within Umcka® has been widely studied by various clinical organizations in patients with common cold and chest cold (bronchial symptoms). These studies show EPs 7630 shortens the duration and reduces severity of throat, nasal and bronchial irritations.


Bronchial Irritations

Patient: Adults & Children

Purpose of Study: Evaluate the effectiveness and safety of EPs 7630 as a treatment for bronchial irritations; this includes symptoms of cough, chest congestion and sputum production.

Result: EPs 7630 was proven to be a safe, effective treatment for both adults and children and ultimately shortened the duration and severity of the illness. Read the full study »


The Common Cold

Patient: Adults

Purpose of Study: Evaluate the effectiveness of EPs 7630 against the common cold (those with symptoms of nasal drainage, sore throat, nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, and fever).

Result: EPs 7630 was proven to be an effective treatment for the common cold. It significantly reduced the severity of symptoms and shortened the duration of the common cold. Read the full study »


Sore Throat

Patient: Children

Purpose of Study: Evaluate the effectiveness of EPs 7630 as a treatment for non-strep sore throat in children.

Result: EPs 7630 was proven to be effective at reducing symptom severity for sore throat and shortened the duration of the illness by at least 2 days. Read the full study »


Umcka ColdCare
 
[x]
 
[x]